ʻO PE-22-28 kahi analog synthetic o spadin, e hōʻike ana i ke kūpaʻa a me ka maikaʻi i hoʻonui ʻia ke hoʻohālikelike ʻia me ka mea kumu.
No ka noiʻi ʻana ma ka TREK-1 (KCNK2) kaila – he lālā o ka lua-pore potassium channel (K2P) ʻohana – hoʻoponopono ia i nā kaʻina hana physiological; ʻO ka neural excitability kekahi o nā mea i hoʻokumu maikaʻi ʻia, me ka ʻike ʻeha, kaumaha, a me nā ʻano ʻano neuroprotection.
Hoʻokumu ʻia nā haʻawina mua sortilin e like me ka protein modulating e pili ana i ka hana TREK-1.
Ua wehewehe ʻia nā noiʻi hou aʻe i kēia hopena ma o ka hoʻokuʻu ʻana o sortilin i kahi propeptide (PE) i loko o ke koko, hoʻopaʻa hope i ka hoʻouna ʻana ma o ke kahawai.
ʻO PE-22-28 ponoʻī he peptide synthetic i loaʻa mai ka ʻoki ʻana a ma hope o ka hoʻololi ʻana i ka ʻāpana ikaika o kēia propeptide..
ʻIke ʻia ke kūpaʻa kiʻekiʻe ma luna o spadin, me ka hana i malamaia no ka oi 23 hola.
Ke hoʻomaka nei nā hoʻokolohua lapaʻau i kēia manawa, akā, hōʻike nā hōʻailona a pau i kahi hanauna hou o nā lāʻau lapaʻau i manaʻo ʻia no ke kaumaha, ʻeha mau a me nā pilikia neurological pili.
Kaʻina
Gly-Val-Ser-Trp-Gly-Leu-Arg
Helu CAS
1801959-12-5
ʻĀpana Molekala
C35H55N11O9
Kaumaha Molekala
773.8930
PE22-28 Imi Pili
1.Hōʻike Therapeutic a me ke koho
ʻOi aku ka maikaʻi o ka hopena lapaʻau i ke kaumaha ma mua o nā antidepressants a pau i aʻo mua ʻia e TREK-1; hōʻailona ʻia ka hoʻopau ʻana i hoʻokahi pūʻulu o nā hōʻailona depressive e ʻike ʻia i loko o nā lā ʻehā, ʻaʻole loa nā hopena ʻaoʻao.
ʻIke ʻia nā hopena neuroprotective, nā wahi liʻiliʻi o ka cerebral infarction a hoʻomaikaʻi (i kekahi degere hiki ke loaa) ʻO ke kaiapuni neural ʻelua mau hopena hiki ke ana.
ʻO ka koho kiʻekiʻe e hana i ka PE-22-28 i kahi laʻana kūpono loa no nā lāʻau lapaʻau TREK-1 e hiki mai ana.
2.Nā hopena antidepressant
Ka pale ʻana i nā ala TREK-1 (e like me ka mea i oleloia maluna) ʻo ia ka mīkini mua.
Depolarization o ka neuronal membrane ma o ka hoʻonui excitability a me ka hopena hoʻonui o synaptic plasticity, ʻO ia ka mea e hoʻohuli ai i nā hiʻohiʻona pathological o ke kaumaha.
ʻO ka pōkole wikiwiki o ka manawa immobility i nā ʻano holoholona he mea hōʻike hōʻike maikaʻi.
TREK-1 ʻiole kīkēkē e hōʻoia hou i ka loulou pololei a me ka hilinaʻi ma ke kahawai.
3.Nā hopena analgesic
Hoʻopili ʻia ka ʻeha mau loa me ka hoʻoulu ʻana o neuronal.
Hōʻike nui ʻia nā ala TREK-1 ma nā neurons sensory mua i loko o nā ala e hoʻokau i ka ʻeha; ganglia aʻa hope (DRG) a ka pepeiaohao hope ʻo ke kuamoʻo he mau laʻana nui.
ʻO kā lākou hoʻāla ʻana he ʻano o ka hoʻoponopono maikaʻi ʻole o nā hōʻailona ʻeha.
ʻO ka hana ʻole a i ʻole ke kāohi nui ʻana i kēia mau awāwa e alakaʻi i ka hauʻoli nui loa i nā ala ʻeha like ʻole. – ʻo ka hoʻokomo ʻana a me ka mālama ʻana i ka ʻeha mau loa he hopena pololei o kēia.
PE-22-28 hoʻololi pono i ka hana o nā kaha calcium i hoʻopaʻa ʻia i ka uila (Nā VGCC) a i ka nui loa Nā mea hoʻokipa NMDA, ma ka depolarizing i kēia mau neurons sensory.
Hoʻololi hou i ka excitability o ke kaapuni neural pili, he 'hooponopono hou’ mai kahi kūlana pathologically hyper-excited ka hopena hopena.
Ua hōʻike nā hoʻokolohua lapaʻau i ke kiʻekiʻe nui o nā paepae ʻeha mechanical a me ka wela (no ka liʻiliʻi loa o nā ʻano ʻeha ʻeha, ʻO ka sciatica kahi haʻawina hoʻohālike) me ka allodynia emi a me ka oiaio hyperalgesia.
4.Nā hopena neuroprotective
ʻAʻole i ʻae ʻia nā hopena neuroprotective hou loa o PE-22-28, akā, hōʻike nā ʻano hana hoʻopaʻa ion channel i kekahi ʻano o ka pale i ka wā o ka ʻeha o ka ʻeha ʻōnaehana nerve.
Wā lōʻihi, paipai ana kumu neurotrophic hōʻike, ʻO nā ala hōʻailona ola a me ka pale ʻana i ka apoptosis i manaʻo ʻia he ʻāpana o kāna hana.
ʻO nā mīkini neuroprotective pololei e hoʻomau i ka wehewehe piha, akā, hōʻike nā hōʻike i ka PE-22-28 ma kahi o ka neuroprotective.
COA
HPLC
MS





